Sanofi Pasteur, a Sanofi Company
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi Pasteur, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count).
Sanofi Pasteur, a Sanofi Company: 153 sponsored US clinical trials, 3 recruiting.
Sanofi Pasteur, a Sanofi Company sponsors 153 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 132 completed. 71 of these trials are in Phase 3-4 (later-stage) and 67 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 16 trials.
Top-decile sponsor footprint
Sanofi Pasteur, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 144 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
153 total, page 3 of 4
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
NCT00952419
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00953524
Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection
NCT00772343
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
NCT00855855
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
NCT00862277
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
NCT00746798
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
NCT00775450
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
NCT00772109
Database Surveillance Safety Study of PENTACEL® Vaccine
NCT00804284
Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
NCT00755274
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00743275
Dose Comparison Study of Menactra® in US Children
NCT00700635
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
NCT00700713
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
NCT00613509
Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
NCT00623181
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
NCT00874549
Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
NCT00561002
Trial to Describe the Safety and Immunogenicity of Fluzone®
NCT00524940
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
NCT00483574
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
NCT00467519
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
NCT00422292
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
NCT00390884
Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
NCT00389532
Trial to Collect Safety Data and Sera for Immunogenicity Testing
NCT00389857
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
NCT00391053
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
NCT00282581
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT00384397
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
NCT00347958
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
NCT00258882
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
NCT00258856
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
NCT00442169
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
NCT00269477
Safety and Immune Response of Different Pediatric Combination Vaccines.
NCT00255047
Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age
NCT00885105
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
NCT00258817
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
NCT00258830
36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
NCT00728260
Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
NCT00254995
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
NCT00858468
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
NCT00777257
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
NCT00258895
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
NCT00643916
Study of Safety and Immunogenicity of Fluzone® in Healthy Children
NCT00831675
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
NCT00831987
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td
NCT00601835
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
NCT00079820
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
NCT00802867
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
NCT00777790
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
NCT00836953
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00835926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 36 |
| Phase 3 | 33 |
| Phase 4 | 38 |
Therapeutic Areas
What is open in the Sanofi Pasteur, a Sanofi Company pipeline
3 recruiting of 153 indexed (2% open); 132 completed (86%).
Phase mix: 71 late (III/IV) vs 67 early (I/II) (balanced across stages).
Top condition: Influenza (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi Pasteur, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 153 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Sanofi Pasteur, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 153 trials (± recruiting share)
- Gynecologic Oncology Group · 154 trials · 1% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- PTC Therapeutics · 2% recruiting · 52 trials
- Spectrum Pharmaceuticals · 2% recruiting · 52 trials
- Carelon Research · 2% recruiting · 50 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
Related
What to do with this Sanofi Pasteur, a Sanofi Company page
153 registered trials is a research-attention snapshot, not an endorsement of Sanofi Pasteur, a Sanofi Company or any single study.
- 3 of Sanofi Pasteur, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Influenza is the condition Sanofi Pasteur, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi Pasteur, a Sanofi Company pipeline card: 153 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.